Advanced Wound Care saw a strong recovery against a weak comparator.

For Q221, according to SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was up, with all segments showing increases,

The US Wound Biologics market, comprising the vast majority of the global biologics market, includes the very competitive skin substitute or CTP (Cellular and/or Tissue-Based Products) market, the Topical Drug/Delivery category and Collagen Dressings. For Q221, the US market was up significantly, with CTPs accounting for the largest share, driven by Organogensis' substantial YoY gains. 

Among the many topics covered in detail in our comprehensive Q221 Advanced Wound Care Market Recap* are:

Changing market dynamics over the past ten years has not held back the robust Skin Substitute/CTP market.

As SmartTRAK celebrates its 10-year anniversary covering AWC and the Biologics area, we look back at the market drivers, products and players to see how the US Skin Substitute market has changed over the last decade. We also look ahead to see what is in store for the Skin Substitute market, which is projected to reach $1.64B in 2025E.

The following is a preview of our Wound Biologics market retrospective. The full article, available on SmartTRAK, features our industry experts discussing and analyzing these changes and trends in detail.

A return to positive growth for the quarter, but gains lag behind pre-COVID-19 levels.

The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Among the many topics covered in detail in our comprehensive Q121 US Infection Prevention - Vascular Access (VA) Adjunct Products Market Recap* are:

Advanced Wound Care begins to stabilize as in-person visits increase and elective procedures rebound.

For Q121, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was up +6.2%, boosted by a strong performance in Biologics, with 3M maintaining the number one position in the AWC space.

Among the many topics covered in detail in our comprehensive Q121 AWC Market Recap* are:

The Symposium on Advanced Wound Care, SAWC, the official meeting of the Wound Healing Society, was held virtually May 10-14 and SmartTRAK attended.

Following is a sampling of some of the takeaways from the meeting that were gathered and curated by our expert analysts and sent out to subscribers in our Daily Updates.

A year of turbulence as COVID-19 affects the WW Advanced Wound Care market at different times and in a variety of ways throughout the year.

For FY20, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was down -1.9% YoY. Q420 grew +1.0%, reflecting the gradual recovery in the market.

Among the many topics covered in the comprehensive Q420/FY20 Advanced Wound Care Market Recap* are:

Anticipated growth for Q4 was weakened by a resurgence of COVID-19 and was not enough to sustain growth with FY20 ending at -3.3% YoY decline.

For FY20, according SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access (VA) Adjunct Products market was down -3.3% YoY, while Q420 revenue was up  +1.2% YoY.

The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Among the many topics covered in the comprehensive Q420/FY20 Infection Prevention: US Vascular Access Adjunct Market* are:

SmartTRAK analyzes how COVID-19 and vaccinations will impact the US Advanced Wound Care Market in 2021.

The impact of COVID-19 on life in the US and its onslaught into the US health care system began in mid-March. CMS and the American College of Surgeons recommended that hospitals, physicians and clinics halt all non-essential medical and surgical procedures, including the treatment of many types of wounds. However, the continual care of a chronic wound is essential for patients to ensure it is on the correct trajectory to heal. Typically, clinicians treat chronic wounds at least once a week to assess the progress of the wound, provide debridement and/or apply CTPs (skin substitutes). The hospital outpatient department (HOPD) wound clinics have been the primary site-of-care to treat these wounds but with the closing of several of these facilities during the initial COVID surge, many patients with chronic wounds were not seen, delayed treatment or began the transfer to the physician office for treatment. In fact, there is some evidence that wounds increased in severity since the start of the pandemic resulting in greater use of higher technology products and unfortunately, an increase in amputations.

The most significant impact on the market occurred in April/May 2020 when several states went into lock down and most, if not all, elective procedures were cancelled. SmartTRAK analyzed the Advanced Wound Care market back in April with the assumption that the peak of COVID-19 would occur during April/May and would slowly return to normal in a v-shaped or hockey-stick shaped recovery. However, data show COVID-19 did not peak solely in the April/May time frame ...

Q3 makes a recovery from Q220 losses but gains remain below pre-COVID levels

For Q320, according to BioMedGPS’ SmartTRAK Financial Dashboard, the US Infection Prevention-Vascular Access Adjunct Products market was down -1.8% YoY. Leading manufacturers in this segment hit hard in Q220 by COVID-19 restrictions and elective procedure cancellations reported positive growth over Q2, but are still not at pre-COVID-19 levels.

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Infection Prevention: US Vascular Access Adjunct Market Recap* are:

In Q320, Advanced Wound Care bounced back to almost normal levels amidst the COVID-19 pandemic with patients returning for chronic wound treatment.

For Q320, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics increased slightly YoY.

3M* remained the WW market leader, up +1.5% YoY, driven by tentative signs of improvement in elective procedures. WW Advanced Dressings returned to positive growth, with mixed performance among leading players. US Skin/Dermal Substitute (CTP) revenue rebounded over Q319, driven by a whopping performance by Organogenesis, while WW NPWT was down slightly YoY, with single-use down and traditional devices flat.

Among the many topics covered in the comprehensive Q320 Advanced Wound Market Recap* are: